Thromb Haemost 1978; 40(02): 260-271
DOI: 10.1055/s-0038-1648661
Original Article
Schattauer GmbH Stuttgart

An International Collaborative Assay of Factor VIII Clotting Activity

T W Barrowcliffe
The National Institute for Biological Standards and Control, Holly Hill, London NW3 6RB
,
T B L Kirkwood
The National Institute for Biological Standards and Control, Holly Hill, London NW3 6RB
› Author Affiliations
Further Information

Publication History

Received 12 April 1978

Accepted 15 April 1978

Publication Date:
12 July 2018 (online)

Summary

An International Collaborative Study was organised to replace the first International Standard for factor VIII. A freeze-dried concentrate, 73/552, and a freeze-dried plasma, 75/510, were assayed against the International Standard, and also compared to fresh normal plasma and local standards.

In assays of the concentrate 73/552 against the first I.S. the mean potency was 1.14 i.u./ ampoule and there was no significant difference between one-stage and two-stage methods. When assayed against average fresh normal plasma, the potency was 1.05 “normal plasma units” per ampoule. It was agreed by the participants that the potency of 73/552 be regarded as the mean of these two figures, i.e. 1.10 i. u./ampoule.

In assays of the freeze-dried plasma, 75/510, against the first I.S. the mean potency was 0. 68 i. u./ampoule, but the one-stage assays gave significantly higher potencies (mean 0.74 1. u./ampoule) than the two-stage assays (mean 0.59 i. u./ampoule). The same trend was also seen in the fresh normal plasmas, and in the local plasma standards. This finding has important implications for the standardisation of factor VIII.

Stability studies on the concentrate 73/552 gave a predicted loss of 0.02% per year at – 20° C. All participants agreed that the material was suitable to serve as an International Standard, and at the 26th meeting of the Expert Committee on Biological Standardisation of the World Health Organization, the material in ampoules coded 73/552 was established as the 2nd International Standard for factor VIII, with a potency of 1.10 i. u./ampoule.

 
  • References

  • 1 Bangham DR, Biggs R, Brozović M, Denson KW E, Skegg JL. 1971; A biological standard for measurement of blood coagulation Factor VIII activity. Bulletin of the World Health Organization 45: 331
  • 2 Bangham DR, Brozović M. 1974; Factor VIII international units and reference materials. Thrombosis et Diathesis Haemorrhagica 31: 3
  • 3 Biggs R, Eveling J, Richards G. 1955; The assay of antihaemophilic globulin activity. British Journal of Haematology 1: 20
  • 4 Bliss CI. 1952. The statistics of bioassay with special reference to the vitamins. Academic Press Inc; New York:
  • 5 Campbell PJ. 1974; International biological standards and reference preparations. II. Procedures used for the production of biological standards and reference preparations. Journal of Biological Standardisation 2: 259
  • 6 Finney DJ. 1952. Statistical method in biological assay. Griffin and Co. Ltd.; London:
  • 7 Kirkwood TB L. 1977; Predicting the stability of biological standards and products. Biometrics 33: 736
  • 8 Kirkwood TB L, Barrowcliffe TW. 1978; Discrepancy between one-stage and two-stage assay of Factor VIII :C. British Journal of Haematology 40: 333
  • 9 Kirkwood TB L, Rizza CR, Snape TJ, Rhymes I, Austen DE G. 1977; Identification of sources of inter-laboratory variation in Factor VIII assay. British Journal of Haematology 37: 559
  • 10 Niemetz J, Nossel HL. 1969; Activated coagulation factors: in vivo and in vitro studies. British Journal of Haematology 16: 337
  • 11 Pool JG, Robinson J. 1959; Assay of plasma antihaemophilic globulin (AHG). British Journal of Haematology 5: 17
  • 12 Seghatchian MJ, Barrowcliffe TW, Miller-Andersson M. 1977; Adsorption of Factor VIII on aluminium hydroxide. Thrombosis and Haemostasis 38: 24
  • 13 World Health Organization Technical Reports Series. 1971; 463: 14
  • 14 World Health Organization Technical Reports Series. 1977; 610: 12